Evidence map›Paper›PMID 36678444›Full record

ArticlePathogens (Basel, Switzerland)2023

Dietary

Masanori Aida, Ryouichi Yamada, Toshiki Matsuo, Itaru Taniguchi, Shin-Ichi Nakamura, Takamitsu Tsukahara

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Frontiers in immunology · 2024
    Trial
  2. Frontiers in veterinary science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Masanori AidaScience & Innovation Center, Mitsubishi Chemical Corporation, Yokohama 227-8502, Kanagawa, Japan.
Ryouichi YamadaScience & Innovation Center, Mitsubishi Chemical Corporation, Yokohama 227-8502, Kanagawa, Japan.
Toshiki MatsuoMitsubishi Chemical Corporation, Tokyo 100-8251, Japan.
Itaru TaniguchiMitsubishi Chemical Corporation, Tokyo 100-8251, Japan.
Shin-Ichi NakamuraKyoto Institute of Nutrition & Pathology, Ujitawara 610-0231, Kyoto, Japan.
Takamitsu TsukaharaKyoto Institute of Nutrition & Pathology, Ujitawara 610-0231, Kyoto, Japan.ORCID 0000-0002-3902-5956

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine the mechanisms by which Weizmannia coagulans SANK70258 (WC) supplementation improved growth performance and coccidial symptoms, we assessed the gene expressions and the microbiota compositions in the small intestinal tissues and digestas of coccidium-infected broilers previously given WC or lasalocid-A sodium (AM). WC supplementation significantly upregulated the gene expressions related to intestinal immunity and barrier functions, such as IL17A, IL17F, IL10, cathelicidin-2 and pIgR. Body weights, and Claudin-1 and IL10 expressions were positively correlated (r = 0.41, p < 0.05 and r = 0.37, p = 0.06, respectively), whereas lesion scores of the small intestine and IL17A expression were negatively correlated (r = −0.33, p = 0.09). The microbiota analysis detected that genus Alistipes was more abundant in WC-supplemented broilers than in control, and positively correlated with body weights and Claudin-1 expression (r = 0.61, p < 0.05 and r = 0.51, p < 0.05, respectively). Intriguingly, genus Enterococcus was most abundant in WC-supplemented broilers and positively correlated with IL17A expression (r = 0.49, p < 0.05). Interestingly, Escherichia-Shigella was significantly more abundant in the small intestinal digestas of AM-administered broilers than in those of control. To summarize, WC supplementation modulated and immunostimulated the microbiotas of broilers, specifically genera Alistipes and Enterococcus, which led to the improvement of weight gain and coccidial symptoms, without disrupting the intestinal microbiota compositions, as AM did.

Indexed as

anti-inflammatory cytokinesbroilersEimeriaintestinal barrier functionWeizmannia coagulans

Identifiers

PMID36678444
PMCPMC9864622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.